DekaBank Deutsche Girozentrale
OREX

DekaBank Deutsche Girozentrale’s Orexigen Therapeutics, Inc. OREX Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-7,400
Closed -$136K – 1149
2015
Q4 		$136K Buy
7,400
+1,100
+17% +$26.2K ﹤0.01% 929
2015
Q3 		$133K Buy
6,300
+300
+5% +$10.3K ﹤0.01% 936
2015
Q2 		$297K Buy
6,000
+200
+3% +$12K ﹤0.01% 805
2015
Q1 		$454K Sell
5,800
-750
-11% -$46.5K 0.01% 743
2014
Q4 		$389K Sell
6,550
-600
-8% -$30.1K ﹤0.01% 746
2014
Q3 		$305K Buy
7,150
+500
+8% +$26.9K ﹤0.01% 752
2014
Q2 		$411K Buy
6,650
+500
+8% +$29.1K 0.01% 644
2014
Q1 		$400K Buy
6,150
+500
+9% +$33.8K 0.01% 612
2013
Q4 		$323K Buy
5,650
+350
+7% +$19.7K 0.01% 604
2013
Q3 		$325K Buy
5,300
+350
+7% +$23.7K 0.01% 595
2013
Q2 		$298K Buy
+4,950
New +$305K 0.01% 494

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

DekaBank Deutsche Girozentrale's OREX Position: Q1 2016 in Review

DekaBank Deutsche Girozentrale sold out of Orexigen Therapeutics, Inc. (OREX) in Q1 2016, closing a stake of 7,400 shares — an estimated $136K sold.

DekaBank Deutsche Girozentrale first reported a position in OREX in Q2 2013 and held it in 11 quarters. The position peaked at $454K in Q1 2015. 104 funds tracked by Wall St. Rank hold OREX as of Q1 2016.

  • DekaBank Deutsche Girozentrale reported no remaining Orexigen Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
  • DekaBank Deutsche Girozentrale sold 7,400 Orexigen Therapeutics, Inc. shares in Q1 2016, an estimated $136K.
  • DekaBank Deutsche Girozentrale first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 11 quarters.
  • DekaBank Deutsche Girozentrale's Orexigen Therapeutics, Inc. position peaked at $454K in Q1 2015.
  • 104 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q1 2016.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q1 2016, filed 13 May 2016.